We are live on !
Find out more
SL
Siren LLC Portfolio holdings
AUM
$4.94B
Turnover
27.78%
1-Year Est. Return
244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
(+37%)
Cap. Flow
+$314M
Cap. Flow % of AUM
Cap. Flow %
6.35%
Top 10 Holdings %
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$82.7M |
| 2 |
Abivax
ABVX
|
+$65.2M |
| 3 |
Hemab Therapeutics
COAG
|
+$57.6M |
| 4 |
Relay Therapeutics
RLAY
|
+$53M |
| 5 |
Kailera Therapeutics
KLRA
|
+$48.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$60.4M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$42.9M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$41.8M |
| 4 |
Revolution Medicines
RVMD
|
+$30.8M |
| 5 |
Kymera Therapeutics
KYMR
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.94% |
| 2 | Technology | 3.57% |
| 3 | Communication Services | 1.85% |
| 4 | Financials | 0.87% |
| 5 | Consumer Discretionary | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Oruka Therapeutics
ORKA
$6.81B
| $23.8M | 0.48% |
+250,000
| New | +$16.7M |
2026 Q2
0 quarters
|
|
52
Seaport Therapeutics
SPTX
$1.15B
| $23.8M | 0.48% |
+1,095,316
| New | +$19.3M |
2026 Q2
0 quarters
|
|
|
DMRA
53
Damora Therapeutics
DMRA
$1.46B
| $23.4M | 0.47% |
900,000
| – | – |
2026 Q1
1 quarter
|
|
54
Tyra Biosciences
TYRA
$1.45B
| $23.2M | 0.47% |
+725,000
| New | +$24M |
2026 Q2
0 quarters
|
|
55
Zura Bio
ZURA
$394M
| $22M | 0.45% |
3,734,866
| – | – |
2025 Q4
2 quarters
|
|
56
TSMC
TSM
$1.95T
| $21.3M | 0.43% |
44,700
+2,500
| +6% | +$1.01M |
2024 Q3
7 quarters
|
|
57
NVIDIA
NVDA
$4.51T
| $19M | 0.38% |
95,000
+5,915
| +7% | +$1.22M |
2024 Q3
7 quarters
|
|
58
Rezolute
RZLT
$375M
| $17.3M | 0.35% |
3,328,287
| – | – |
2026 Q1
1 quarter
|
|
59
MapLight Therapeutics
MPLT
$385M
| $16.1M | 0.33% |
450,000
| – | – |
2025 Q4
2 quarters
|
|
60
Neumora Therapeutics
NMRA
$94.6M
| $14.4M | 0.29% |
8,497,822
| – | – |
2024 Q3
7 quarters
|
|
61
Nebius Group N.V.
NBIS
$35.2B
| $14.4M | 0.29% |
52,000
-61,614
| -54% | -$12.2M |
2024 Q4
6 quarters
|
|
62
Microsoft
MSFT
$3.94T
| $14M | 0.28% |
37,500
-3,880
| -9% | -$1.57M |
2024 Q3
7 quarters
|
|
63
CytomX Therapeutics
CTMX
$477M
| $13M | 0.26% |
3,457,711
| – | – |
2026 Q1
1 quarter
|
|
64
Generate Biomedicines
GENB
$1.68B
| $12.4M | 0.25% |
736,104
| – | – |
2026 Q1
1 quarter
|
|
65
Inhibikase Therapeutics
IKT
$209M
| $11.9M | 0.24% |
5,850,000
| – | – |
2025 Q4
2 quarters
|
|
66
Adagene
ADAG
$134M
| $11.2M | 0.23% |
+2,666,666
| New | +$10M |
2026 Q2
0 quarters
|
|
67
enGene Therapeutics
ENGN
$117M
| $10.8M | 0.22% |
6,256,662
+1,003,503
| +19% | +$4.09M |
2025 Q4
2 quarters
|
|
68
Whitehawk Therapeutics
WHWK
$178M
| $10.7M | 0.22% |
2,337,102
+255,102
| +12% | +$1.06M |
2025 Q1
5 quarters
|
|
69
Datadog
DDOG
$64.3B
| $10.4M | 0.21% |
40,000
-14,300
| -26% | -$2.66M |
2024 Q3
7 quarters
|
|
70
ServiceNow
NOW
$106B
| $9.9M | 0.2% |
100,000
+12,910
| +15% | +$1.28M |
2024 Q3
7 quarters
|
|
71
Broadcom
AVGO
$1.4T
| $9.44M | 0.19% |
25,000
+10,000
| +67% | +$4.01M |
2025 Q4
2 quarters
|
|
72
IonQ
IONQ
$14B
| $9.05M | 0.18% |
170,000
| – | – |
2024 Q3
7 quarters
|
|
|
73
CALL
Microsoft
MSFT
$3.94T
| $8.95M | 0.18% |
+24,000
| New | +$9.7M |
2026 Q2
0 quarters
|
|
74
JFrog
FROG
$12.5B
| $8.68M | 0.18% |
95,500
-33,316
| -26% | -$2.16M |
2024 Q3
7 quarters
|
|
75
Oculis Holding
OCS
$417M
| $8.67M | 0.18% |
+625,000
| New | +$14.2M |
2026 Q2
0 quarters
|
|
Similar funds
Siren LLC's Q2 2026 Portfolio in Review
As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.
- Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
- Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
- Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
- Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
- Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
- Siren LLC opened 26 new positions and closed 9 in Q2 2026.
- Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.
Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.